Lilly once again beats expectations as tirzepatide accounts for 64% of revenue
Eli Lilly posted $23 billion in second-quarter revenues, coming in about $3 billion above analysts' estimates. Lilly also once again raised its full-year revenue guidance to between $85 billion and $87 ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.